Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938246 · ClinicalTrials.gov registry record · Phase 2
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Sagimet Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT03938246 is a Phase 2 study that has completed, run by Sagimet Biosciences. The registered enrollment target is 142 participants.
The verdict
NCT03938246, a Phase 2 study, has completed, sponsored by Sagimet Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of three doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.
Interventions
- DRUG TVB-2640 25 mg (US)
- DRUG TVB-2640 50 mg (US)
- DRUG Placebo (US)
- DRUG TVB-2640 50 mg (China)
- DRUG Placebo (China)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2021-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03938246
The ClinicalTrials.gov registry entry for NCT03938246 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sagimet Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which TVB-2640 25 mg (US) is the first listed.
NCT03938246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03938246 about?
NCT03938246 is a clinical study titled "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)". This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of t...
What is the current status of trial NCT03938246?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2019-03-22. Estimated completion is 2021-10-02.
What interventions are being tested in trial NCT03938246?
The interventions under investigation include: TVB-2640 25 mg (US) (DRUG), TVB-2640 50 mg (US) (DRUG), Placebo (US) (DRUG), TVB-2640 50 mg (China) (DRUG), Placebo (China) (DRUG).
Who is sponsoring clinical trial NCT03938246?
This trial is sponsored by Sagimet Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.